|[February 28, 2013]
Diaxonhit solidifies its position as a major player in the field of transplantation
PARIS --(Business Wire)--
Diaxonhit (Paris:ALEHT), the leading French provider of specialty
diagnostic solutions, announces the award to its marketing affiliate,
InGen, of four national public tenders from the French Blood Bank (EFS).
They involve supplying the EFS with tests necessary to perform HLA(1)
typing and monitoring in the field of transplantation. These tenders
cover the next four years, and represent potential revenues of up to €
13.8 million by the end of 2016.
"HLA tests represent a major activity of Diaxonhit, and the selection of
our commercial subsidiary InGen by EFS, a recognized institution and a
key player in transplantation in France, reflects the quality of our
offering and strengthens our position in this specialty. Within the
newly formed group, our strategy includes developing our activities in
the broader context of transplantation and immunology," said Loïc
Maurel, CEO of Diaxonhit.
Transplantation in France
The field of transplantation covers activities related to organ (kidney,
heart, lung, etc...) and bone marrow transplantion (treatment of
leukemia, hematological diseases, etc...). In 2011, 4,954 transplants
were carried out in France, with an additional 16,371 patients awaiting
transplantation (2). This number increases by about 4% per
year (3). Management of volunteer donors and recipients is
performed by the French Biomedicine Agency that maintains corresponding
centralized national registries.
Transplant rejection: transplantation primary risk
On the surface of their own cells, every individual possesses a set of
markers called HLA that enable the immune system to distinguish self
from non-self (foreign bodies) and to not reject the latter. All of
these markers and corresponding genes constitute the individual HLA
system. During transplantation, if donor and recipient HLA's are not
compatible, the recipient's immune system will reject transplanted cells
by destroying them. Rejection is therefore the main transplantation
risk, the rate of acute rejection at one year after transplant ranging
between 5% (kidney) and 50% (lung) (3).
Typing and monitoring tests: critical contribution to transplantation
In order to assess compatibility between donors and recipients before
transplantation, and to reduce the risk o rejection, HLA analyses are
routinely performed using serology or molecular biology. Monitoring of
transplant patients and monitoring of rejections are also performed by
measuring the presence of anti-HLA antibodies and monitoring them in
recipients before and after transplantation. Post-transplantation
monitoring is used to adjust immunosuppressive treatments whose side
effects can be significant. All these tests are performed in the HLA
laboratories of blood transfusion centers (18 centers in France) or
histocompatibility (Immunology) laboratories of university hospitals (20
laboratories in France and associated territories).
Diaxonhit: leader in France for tests related to transplantation
The supply of organ typing and anti-HLA antibody monitoring tests to
blood centers grouped under the umbrella of the EFS is part of the
renewed tenders that will benefit InGen. In addition, InGen was also
selected by the EFS for supplying tests and related equipment for
intermediate resolution molecular typing of volunteer bone marrow donors.
Diaxonhit is currently the leading supplier of HLA laboratories, with
over 70% market share in the French territory. Its partner is One Lambda
(USA), the world leader for HLA tests and part of Thermo Fisher
Scientific since mid-2012.
(1) Human Leucocyte Antigen
(2) Source (News - Alert) : French Biomedicine Agency, www.dondorganes.fr/016-les-chiffres-cles
(3) Source : Inserm, www.inserm.fr/thematiques/sante-publique/dossiers-d-information/transplantation-d-organes
Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully
integrated leader in the in-vitro diagnostic field, involved from
research to commercialization of specialty diagnostic products.
With many partnerships and a strong presence in hospitals, Diaxonhit has
an extensive commercialization network. Through its affiliate, InGen, it
commercializes and services, mostly under exclusivity agreements,
in-vitro diagnostic kits and advanced equipment. It operates mainly in
the fields of transplantation, infectious diseases and autoimmunity,
product quality control and rapid tests, including Tetanus Quick Stick
®, a proprietary product.
The group also owns a diversified portfolio of products in development,
including both innovative molecular and non-molecular diagnostics,
covering three main specialty areas: immuno-infection, Alzheimer's
disease and cancer.
Diaxonhit headquarters are located in Paris and its affiliate in the
Paris region. The Group is listed on NYSE Alternext in Paris and is part
of the NYSE Alternext OSEO innovation index.
For more information, please visit: http://www.diaxonhit.com.
This press release contains elements that are not historical facts
including, without limitation, certain statements about future
expectations and other forward-looking statements. Such statements are
based on management's current views and assumptions and involve known
and unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those anticipated.
In addition, Exonhit, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the
accuracy of, and make no representations or warranties in relation to,
statistical data or predictions contained in this press release that
were taken or derived from third party sources or industry publications,
and such statistical data and predictions are used in this press release
for information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French
language version shall prevail.
[ Back To TMCnet.com's Homepage ]